RxDoctor Payments Data

Debra Sudan, MD

Transplant Surgery · Durham, NCNPI 1902856651

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Shire North American Group Inc accounts for 61.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $4,926 and has fallen 57.9% since, to $2,072 in 2025.

$7,909in general payments, 2019–2025

Across 13 payments — averaging $608.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$5K
  • Transmedics, Inc.$3K
  • Novartis$428
  • Veloxis Pharmaceuticals, Inc.$50
$1,060,673in research payments, 2019–2025

Across 227 payments — averaging $4672.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Transmedics, Inc.$386K
  • Organox Ltd$175K
  • Novartis$171K
  • Takeda Pharmaceuticals U.S.A., Inc.$110K
  • Paragonix Technologies, Inc.$73K
  • Vectivbio AG$72K
  • plus $74K from 2 others

What the payments were for

  • Consulting fees$4,00051%
  • Travel & lodging$3,66846%
  • Food & beverage$2413%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,117
Medicare patients
16
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other transplant surgery in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →